{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:01:54Z","timestamp":1784818914521,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2021-08-12"],"award-info":[{"award-number":["320.6750.2021-08-12"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinthera.2025.08.017","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T06:25:08Z","timestamp":1758695108000},"page":"1061-1068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Direct Oral Anticoagulants in Patients After Heart Valve Replacement or Repair: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Weiqi","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2972-1069","authenticated-orcid":false,"given":"Weihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.08.017_bib0001","first-page":"32","article-title":"Valvular heart disease epidemiology","volume":"10","author":"Aluru","year":"2022","journal-title":"Med Sci"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0002","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s10354-021-00845-7","article-title":"Anticoagulation after heart valve replacement","volume":"173","author":"Voss","year":"2023","journal-title":"Wiener Med Wochenschr"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0003","first-page":"e35","article-title":"2020 ACC\/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0004","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","article-title":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"135","author":"Gelosa","year":"2018","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0006","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtcvs.2021.01.127","article-title":"Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial","volume":"165","author":"Shim","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0007","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.amjmed.2021.08.026","article-title":"Non-vitamin K antagonists versus warfarin in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis","volume":"135","author":"Cardoso","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0008","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0009","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0010","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0011","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0012","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0013","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1161\/CIRCULATIONAHA.116.026714","article-title":"Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves","volume":"135","author":"Carnicelli","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0014","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","article-title":"Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study","volume":"16","author":"Dur\u00e3es","year":"2016","journal-title":"Drugs R&D"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/clc.23178","article-title":"Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial","volume":"42","author":"Guimar\u00e3es","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0016","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0017","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1253\/circj.CJ-22-0093","article-title":"Edoxaban vs. vitamin K antagonist for atrial fibrillation after transcatheter aortic valve replacement in Japanese patients\u2014a subanalysis of the ENVISAGE-TAVI AF trial","volume":"86","author":"Watanabe","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0018","doi-asserted-by":"crossref","first-page":"355","DOI":"10.5603\/CJ.a2021.0158","article-title":"NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement","volume":"29","author":"Piepiorka-Broniecka","year":"2022","journal-title":"Cardiol J"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0019","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.amjcard.2021.01.016","article-title":"Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves","volume":"146","author":"Duan","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ehjcvp\/pvz064","article-title":"Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation","volume":"7","author":"Butt","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0022","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1253\/circj.CJ-22-0226","article-title":"Comparison of direct oral anticoagulants and warfarin in patients with atrial fibrillation and an aortic bioprosthetic valve","volume":"86","author":"Miyake","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0023","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40261-020-00939-x","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements","volume":"40","author":"Pasciolla","year":"2020","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0024","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jtcvs.2023.03.004","article-title":"Direct oral anticoagulants for atrial fibrillation in early postoperative valve repair or bioprosthetic replacement","volume":"168","author":"Moser","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0025","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/j.clinthera.2019.10.008","article-title":"Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves","volume":"41","author":"Russo","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0026","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11239-020-02046-2","article-title":"Rivaroxaban in patients undergoing surgical mitral valve repair","volume":"49","author":"Noohi","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0027","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00392-018-1247-x","article-title":"NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation","volume":"107","author":"Geis","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0028","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes after transcatheter aortic valve replacement","volume":"12","author":"Jochheim","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0029","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jcin.2021.05.025","article-title":"TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist?","volume":"14","author":"Didier","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11239-019-01968-w","article-title":"Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry","volume":"50","author":"Kalogeras","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023561","article-title":"Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: insights from the STS\/ACC TVT registry","volume":"11","author":"Tanawuttiwat","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268113","article-title":"Effectiveness and safety of non-vitamin K direct oral anticoagulants in atrial fibrillation patients with bioprosthetic valve","volume":"17","author":"Moon","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0033","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/heartjnl-2023-322548","article-title":"Direct oral anticoagulants versus vitamin K antagonist after transcatheter aortic valve implantation","volume":"109","author":"Hohmann","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0034","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.athoracsur.2022.07.045","article-title":"Apixaban for anticoagulation after robotic mitral valve repair","volume":"115","author":"Mazur","year":"2023","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0035","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcin.2016.10.023","article-title":"Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement","volume":"10","author":"Seeger","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.698784","article-title":"Anticoagulation therapy after biologic aortic valve replacement","volume":"8","author":"Myllykangas","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"Fi1","key":"10.1016\/j.clinthera.2025.08.017_bib0037","doi-asserted-by":"crossref","first-page":"f93","DOI":"10.1093\/ehjcvp\/pvaa011","article-title":"All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease","volume":"7","author":"Strange","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0038","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1253\/circj.CJ-21-0564","article-title":"Antithrombotic therapy for patients with atrial fibrillation and bioprosthetic valves\u2014real-world data from the multicenter, prospective, observational BPV-AF registry","volume":"86","author":"Izumi","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0039","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jjcc.2020.02.006","article-title":"Registry of antithrombotic therapy in atrial fibrillation patients with bioprosthetic valves: a retrospective observational study","volume":"76","author":"Izumi","year":"2020","journal-title":"J Cardiol"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.14423\/SMJ.0000000000001193","article-title":"Efficacy and safety of nonvitamin K oral anticoagulants following cardiac valve replacement","volume":"114","author":"Stuart","year":"2021","journal-title":"Southern Med J"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0041","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.athoracsur.2021.03.016","article-title":"New oral anticoagulants versus warfarin in atrial fibrillation after early postoperative period in patients with bioprosthetic aortic valve","volume":"113","author":"Mannacio","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0042","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.amjcard.2018.12.042","article-title":"Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implantation and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation","volume":"123","author":"Mangner","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0043","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jcin.2019.06.001","article-title":"Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation","volume":"12","author":"Kosmidou","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0044","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00228-022-03371-6","article-title":"A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation","volume":"78","author":"Ooi","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.899906","article-title":"An updated meta-analysis of DOACs vs. VKAs in atrial fibrillation patients with bioprosthetic heart valve","volume":"9","author":"Cao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0046","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/02676591231202383","article-title":"Direct oral anticoagulants versus vitamin K antagonists: which one is more effective in atrial fibrillation","volume":"39","author":"Khodadadiyan","year":"2024","journal-title":"Perfusion"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0047","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0048","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.3390\/jcm12247632","article-title":"Antithrombotic management for transcatheter aortic valve implantation","volume":"12","author":"Ya'Qoub","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0049","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1080\/03007995.2018.1467885","article-title":"Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban","volume":"34","author":"Camm","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0050","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/eurheartj\/ehaa1075","article-title":"Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"42","author":"Galiuto","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.08.017_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.764356","article-title":"Direct acting oral anticoagulant vs. warfarin in the prevention of thromboembolism in patients with non-valvular atrial fibrillation with valvular heart disease-a systematic review and meta-analysis","volume":"8","author":"Martha","year":"2021","journal-title":"Front Cardiovasc Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:54:43Z","timestamp":1774947283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825003054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0149291825003054"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.08.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Direct Oral Anticoagulants in Patients After Heart Valve Replacement or Repair: A Systematic Review and Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}